The Trump administration advanced federal marijuana policy in April 2026 when Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I began June 29, 2026, and closed its record by July 15. All participating parties were opponents of reform, yet DEA counsel in post-hearing briefs urged the administrative law judge to recommend Schedule III, citing accepted medical use and safety under supervision. The ALJ’s recommended decision remains pending before the DEA Administrator, after which a final rule could face further litigation in federal court. No timeline for completion has been announced.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$812,546 Vol.
31 dic 2026
30 settembre
2%
31 dicembre
23%
$812,546 Vol.
30 settembre
$739 Vol.
2%
31 dicembre
$202,236 Vol.
23%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced federal marijuana policy in April 2026 when Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I began June 29, 2026, and closed its record by July 15. All participating parties were opponents of reform, yet DEA counsel in post-hearing briefs urged the administrative law judge to recommend Schedule III, citing accepted medical use and safety under supervision. The ALJ’s recommended decision remains pending before the DEA Administrator, after which a final rule could face further litigation in federal court. No timeline for completion has been announced.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Feb 7, 2026, 5:04 PM ET
Volume
$812,546Data di fine
1 gen 2027Mercato aperto
Feb 7, 2026, 5:04 PM ETRisolutore
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced federal marijuana policy in April 2026 when Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I began June 29, 2026, and closed its record by July 15. All participating parties were opponents of reform, yet DEA counsel in post-hearing briefs urged the administrative law judge to recommend Schedule III, citing accepted medical use and safety under supervision. The ALJ’s recommended decision remains pending before the DEA Administrator, after which a final rule could face further litigation in federal court. No timeline for completion has been announced.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$812,546Data di fine
1 gen 2027Mercato aperto
Feb 7, 2026, 5:04 PM ETRisolutore
0x65070BE91...The Trump administration advanced federal marijuana policy in April 2026 when Acting Attorney General Todd Blanche issued a final order immediately moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III. A separate expedited DEA administrative hearing on broader rescheduling of all marijuana from Schedule I began June 29, 2026, and closed its record by July 15. All participating parties were opponents of reform, yet DEA counsel in post-hearing briefs urged the administrative law judge to recommend Schedule III, citing accepted medical use and safety under supervision. The ALJ’s recommended decision remains pending before the DEA Administrator, after which a final rule could face further litigation in federal court. No timeline for completion has been announced.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti